ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Tuesday, February 8, 2022
At the Board meeting of the Company held on Tuesday, February 8, 2022 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended December 31, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated February 8, 2022 are enclosed herewith. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Change in Directorate
As required under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we would like to inform you that Ms. Kimsuka Narsimhan (DIN: 02102783), Independent Director of the Company, retired as Director of the Company, upon completion of her term of office, at the close of business hours on February 1, 2022. The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 are provided in Annexure - A. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday, February 8, 2022
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2022 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, February 8, 2022 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2021 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from December 16, 2021 to February 11, 2022 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.
Immune response induced by Omicron effectively neutralise Delta variant: ICMR study
The study was conducted on 39 individuals, of which 25 had taken both the doses of AstraZeneca COVID-19 vaccine, eight people had taken double dose of Pfizer jab, while six were unvaccinated. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith Certificate dated January 3, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholding for the Period Ended December 31, 2021
AstraZeneca Pharma India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here ASTRAZENECA PHARMA INDIA LTD. - 506820 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- PRATAP RUDRADesignation :- Company Secretary and Compliance Officer
COVID-19 vaccine booster provides effective antibody protection against Omicron: Lancet study
Researchers from Francis Crick Institute and the National Institute for Health Research (NIHR), UK, found that antibodies generated in people who had received only two doses of either the AstraZeneca or the Pfizer vaccine were less able to neutralise Omicron as compared to Alpha and Delta variants.
AstraZeneca booster generates higher antibodies against Omicron: Data
The increased response was seen in people who were previously vaccinated with either Vaxzevria or an mRNA vaccine, the drugmaker said ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Change in Directorate
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015), we wish to inform you that the Board of Directors of the Company based on the recommendations of Nomination and Remuneration Committee, approved the appointment of Ms. Shilpa Shridhar Divekar (DIN: 06619353) as an Additional Director (Non-executive & Independent) of the Company w.e.f December 29, 2021.